Further Analysis of Phase 2 PTSD Results
February 18, 2019
Half Yearly Report and Accounts
February 15, 2019
Appendix 4C - quarterly
January 31, 2019
BNO at Neuroscience Innovation Forum and Biotech Showcase
January 4, 2019
BNC105 Clinical Trial In Combination With Nivolumab
January 4, 2019
Bionomics Receives $650k Licensing Revenue from CTx
December 21, 2018
Appendix 3B
December 13, 2018
Bionomics Receives Over $6.5m R&D Tax Incentive Refund
December 11, 2018
Historical ASX announcements can be found here.